- $1.65bn
- $1.60bn
- $465.31m
- 81
- 33
- 99
- 82
Annual cashflow statement for AtriCure, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -48.2 | 50.2 | -46.5 | -30.4 | -44.7 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 25.4 | -69.6 | 31.5 | 38.3 | 56.5 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.64 | -4.85 | -18.9 | -18.2 | -18.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -19.9 | -13.8 | -22.1 | 4.48 | 12.2 |
| Capital Expenditures | -5.26 | -9.75 | -16.9 | -42 | -23.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -151 | 33.3 | 60.9 | 63.8 | 53.7 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -156 | 23.5 | 44 | 21.8 | 30.2 |
| Financing Cash Flow Items | -13.1 | -19.2 | -12.2 | -6.62 | -8.02 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 189 | -7.64 | -7.06 | -0.032 | -3.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.5 | 1.71 | 14.4 | 26.2 | 38.4 |